A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adult growth hormone deficiency (AGHD)

Trial Profile

A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adult growth hormone deficiency (AGHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs GX H9 (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors Genexine
  • Most Recent Events

    • 04 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of this study and interim results of another phase II study in patients with PGHD, presented at The 99th Annual Meeting of the Endocrine Society
    • 02 Apr 2017 According to a Genexine and Handok media release, the company presented interim results from this study at the 99th Annual Meeting of the Endocrine Society for Pediatric Endocrinology (ENDO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top